Q32 Bio Inc. (QTTB)
Company Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.
The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders.
Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.
Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Country | United States |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Arthur Tzianabos |
Contact Details
Address: One Patriots Park Bedford, Massachusetts 01730 United States | |
Phone | 781-301-7277 |
Stock Details
Ticker Symbol | QTTB |
Exchange | NASDAQ |
Fiscal Year | January - December |
CIK Code | 0001661998 |
CUSIP Number | 438083107 |
ISIN Number | US4380831077 |
Employer ID | 47-3468154 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Paul Alloway J.D., Ph.D. | President and Chief Operating Officer |
Dr. Saswati Chatterjee Ph.D. | Co-Founder and Member of Scientific Advisory Board |
Charles Michaud Jr., CPA | Vice President of Finance, Corporate Controller and Treasurer |
Theresa McNeely | Chief Communications Officer and Patient Advocate |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
Mar 27, 2024 | 8-K | Current Report |
Mar 22, 2024 | 8-K/A | [Amend] Current report |
Mar 20, 2024 | 8-K | Current Report |
Mar 15, 2024 | 8-K | Current Report |
Mar 14, 2024 | SCHEDULE 13G | Filing |
Mar 13, 2024 | POS EX | Filing |
Mar 13, 2024 | 424B3 | Prospectus |
Mar 13, 2024 | 10-K | Annual Report |
Mar 11, 2024 | 425 | Filing |